Allarity Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Allarity Therapeutics, Inc. Overview

Allarity Therapeutics is a Phase 2 clinical-stage pharmaceutical company developing stenoparib (2X-121), a dual PARP and WNT pathway inhibitor. The company develops drugs for personalized cancer treatment using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. This precision medicine approach aims to enhance therapeutic benefit by identifying patients most likely to respond to treatment.

Strategic Profile

In Q2 2026, Allarity secured key U.S. patent coverage of its stenoparib-specific DRP® companion diagnostic, providing exclusivity into April 2042 and establishing a long-term intellectual property foundation. In Q2 2026, the company achieved CLIA certification for in-house DRP® testing, expected to reduce costs and turnaround times while supporting U.S. clinical trials including ovarian cancer registrational studies. The company is positioned as a targeted oncology player leveraging AI-driven patient selection to improve clinical outcomes and commercial probability.

Competitive Landscape

Allarity competes with other oncology biotech firms including Kura Oncology, Bristol-Myers Squibb, Sutro Biopharma, and others in the targeted cancer drug space. The company differentiates through its dual PARP/WNT pathway inhibition and proprietary DRP patient selection technology, positioning stenoparib as a precision oncology asset with potential multi-indication application.

Industry Context

Allarity Therapeutics, Inc. operates in Biotechnology.

Key facts

Headquarters: Tarpon Springs, Florida, US · Revenue: Estimated $320K (trailing twelve months as of end-2025) · Market cap: $23.3M (as of May 2026)